Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery

Drug Discovery Today

Volumn 10, Issue 6, 2005, Pages 409-416

  Slon Usakiewicz, Jacek J ^a   Ng, William ^a   Dai, Jin Rui ^a   Pasternak, Andrew ^a   Redden, Peter R ^a  

^a Protana Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTIBODY; BETA GALACTOSIDASE; ESTROGEN RECEPTOR BETA; IDITOL DEHYDROGENASE; LECTIN; LIGAND; NEW DRUG; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; PROTEIN TYROSINE KINASE;

ANALYTIC METHOD; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; BIOLOGY; CHEMICAL LABELING; CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONFORMATION; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG SCREENING; EVALUATION; FRONTAL AFFINITY CHROMATOGRAPHY WITH MASS SPECTROMETRY; IC 50; INHIBITION KINETICS; MASS SPECTROMETRY; MEASUREMENT; MONITORING; PARAMETER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; TIME;

BINDING SITES; CHROMATOGRAPHY, AFFINITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LIGANDS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEINS;

EID: 15944412467     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03360-4     Document Type: Review

References (42)

1. Geoghegan, K. and Kelly, M.A. Biomedical applications of mass spectroscopy in pharmaceutical drug discovery. Mass Spectrom. Rev. (in press)
2. Siegel M.M. Early discovery drug screening using mass spectrometry. Curr. Top. Med. Chem. 2:2002;13-33
3. Min D-H., et al. Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. 22:2004;717-723
4. Boguslavsky J. HTS assay development: Is smaller really better? Drug Discov. Dev. 7:2004;37-40
5. Gribbon P., et al. Fluorescence readouts in HTS: no gain without pain? Drug Discov. Today. 8:2003;1035-1043
6. Hill D.C. Trends in development of high-throughput screening technologies for rapid discovery of novel drugs. Curr. Opin. Drug Discov. Dev. 1:2003;92-97
7. Schriemer D.C., et al. Micro-scale frontal affinity chromatography with mass spectrometric detection: a new method for the screening of compound libraries. Angew. Chem. Int. Ed. Engl. 37:1998;3383-3387
8. Hage D.S. Chromatographic approaches to immunoassays. J. Clin. Ligand Assay. 20:1997;293-301
9. Hage D.S., Tweed S.A. Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions. J. Chromatogr. B Biomed. Sci. Appl. 699:1997;499-525
10. Schreimer D.C., Hindsgaul O. Deconvolution approaches in screening compound mixtures. Comb. Chem. High Throughput Screen. 1:1998;155-170
11. Zhang Y., et al. Immobilized nicotinic receptor stationary phase for on-line liquid chromatographic determination of drug-receptor affinities. Anal. Biochem. 264:1998;22-25
12. Kasai K.I., Oda Y. Frontal affinity chromatography theory for its application to studies on specific interactions of biomolecules. J. Chromatogr. B Biomed. Sci. Appl. 376:1986;33-47
13. Zhu L., et al. Frontal affinity chromatography combined on-line with mass spectrometry: a tool for the binding study of different epidermal growth factor receptor inhibitors. Anal. Chem. 75:2003;6388-6393
14. d determination and screening of α-gal derivatives binding to anti-gal antibodies (IgG). J. Carbohydr. Chem. 22:2003;347-376
15. Luo H., et al. Frontal immunoaffinity chromatography with mass spectrometric detection: A method for finding active compounds from traditional Chinese herbs. Anal. Chem. 75:2003;3994-3998
16. Chan N.W.C., et al. Frontal affinity chromatography for the screening of mixtures. Comb. Chem. High Throughput Screen. 5:2002;395-406
17. Chan N.W.C., et al. Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. Anal. Biochem. 319:2003;1-12
18. Zhang B., et al. Rapid determination of the binding affinity and specificity of the mushroom Polyporus squamosus lectin using frontal affinity chromatography coupled to electrospray mass spectrometry. Glycobiology. 11:2001;141-147
19. Rich R.L., et al. Kinetic analysis of estrogen receptor/ligand interactions. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8562-8567
20. Slon-Usakiewicz J.J., et al. Frontal affinity chromatography with MS detection (FAC-MS) of EphB2 Tyrosine Kinase Receptor. 1. Comparison with conventional ELISA. J. Med. Chem. 47:2004;5094-5100
21. Shah A. How to choose an in vitro kinase assay in Drug Discov. Dev. 2004;59-62. March
22. c-src tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg. Med. Chem. Lett. 10:2000;477-481
23. Slon-Usakiewicz, J.J. et al. (2004) Hybrid approach incorporating in silico and frontal affinity chromatography with MS detection (FAC-MS) screening of EphB2 tyrosine kinase receptor. SBS 10th Anniversary Conference and Exhibition, 11-16 September 2004, Orlando FL, USA. p.1011
24. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365
25. Schlessinger J. Signal transduction. Autoinhibition control. Science. 300:2003;750-752
26. Toledo L.M., et al. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 6:1999;775-805
27. Nagar B., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243
28. Noble M.E.M., et al. Protein kinase inhibitors: insights into drug design from structure. Science. 303:2004;1800-1805
29. Slon-Usakiewicz, J.J. et al. Global kinase screening - new applications of Frontal Affinity Chromatography coupled to Mass Spectrometry (FAC-MS) in drug screening. Anal. Chem. (in press)
30. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5:2004;464-471
31. Ferguson K.M., et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11:2003;507-517
32. Wybenga-Groot L.E., et al. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell. 106:2001;745-757
33. Roberts G.C.K. Applications of NMR in drug discovery. Drug Discov. Today. 5:2000;230-240
34. Pochapsky S.S., et al. Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition. Curr. Top. Med. Chem. 1:2001;427-441
35. Powers R. Application of NMR to structure-based drug design in structural genomics. J. Struct. Funct. Genomics. 2:2002;113-123
36. Stockman B.J., et al. NMR screening techniques in drug discovery and drug design. Progr. NMR Spectrosc. 41:2002;187-231
37. Mattei B., et al. Biomolecular interaction analysis and MS. Anal. Chem. 76:2004;19A-25A
38. Annis, D.A. et al. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem. Soc. 126, 15495-15503
39. Lai K-O., et al. Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signalling in muscle. J. Biol. Chem. 279:2004;13383-13392
40. Hodgson R.J., et al. Protein-doped monolithic silica columns for capillary liquid chromatography prepared by the sol-gel method: Applications to frontal affinity chromatography. Anal. Chem. 76:2004;2780-2790
41. Cruz-Aguado J.A., et al. Entrapment of Src protein tyrosine kinase in sugar-modified silica. Anal. Chem. 76:2004;4182-4188
42. Gill I. Biol.-doped nanocomposite polymers: Sol-Gel bioencapsulates. Chem. Mater. 13:2001;3404-3421